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Background: The malaria vaccine RTS,S induces antibodies against the Plasmodium falciparum circumsporozoite
protein (CSP) and the concentration of Immunoglobulin G (IgG) against the repeat region of CSP following vaccination
is associated with protection from P. falciparum malaria. So far, only the quantity of anti-CSP IgG has been measured
and used to predict vaccination success, although quality (measured as avidity) of the antigen-antibody interaction shall
be important since only a few sporozoites circulate for a short time after an infectious mosquito bite, likely requiring fast
and strong binding.
Methods: Quantity and avidity of anti-CSP IgG in African infants who received RTS,S/AS01E in a 0-1-2-month or a
0-1-7-month schedule in a phase 2 clinical trial were measured by enzyme-linked immunosorbent assay. Antibody
avidity was defined as the proportion of IgG able to bind in the presence of a chaotropic agent (avidity index). The
effect of CSP-specific IgG concentration and avidity on protective efficacy was modelled using Cox
proportional hazards.
Results: After the third dose, quantity and avidity were similar between the two vaccination schedules. IgG avidity after
the last vaccine injection was not associated with protection, whereas the change in avidity following second and third
RTS,S/AS01E injection was associated with a 54% risk reduction of getting malaria (hazard ratio: 0.46; 95% confidence
interval (CI): 0.22-0.99) in those participants with a change in avidity above the median. The change in anti-CSP
IgG concentration following second and third injection was associated with a 77% risk reduction of getting malaria
(hazard ratio: 0.23, 95% CI: 0.11-0.51).
Conclusions: Change in IgG response between vaccine doses merits further evaluation as a surrogate marker for
RTS,S efficacy.
Trial registration: ClinicalTrials.gov Identifier NCT00436007.
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Malaria has an enormous public health impact and new
preventive interventions are urgently needed. After more
than 100 years of research on malaria vaccines, RTS,S
was the first pre-erythrocytic vaccine candidate that en-
tered phase III clinical development [1-3]. RTS,S con-
tains hepatitis B surface antigen (HBsAg) together with a
fusion protein of HBsAg and a carboxy-terminal frag-
ment of Plasmodium falciparum circumsporozoite pro-
tein (CSP), co-expressed in yeast and formulated with a
proprietary adjuvant (AS01). The exact mechanism of
RTS,S-mediated protection is not known, although Im-
munoglobulin G antibodies (IgG) against the CSP repeat
region are likely to play an important role since the con-
centration of anti-CSP IgG partly explains protection in
most studies that assessed efficacy of RTS,S in African
children [4-6]. In addition, passive transfer of anti-CSP
IgG can protect animals from subsequent challenge
[7,8]. Besides concentration, many other properties de-
termine antibody function. Among them are availability
of effector molecules, post-translational modification,
isotype, subclass, affinity and avidity of antibodies. It is
difficult to measure all these characteristics in one sam-
ple, particularly in the small sample volumes obtained
during clinical trials in infants. Affinity, defined as the
strength of interaction between an epitope and an anti-
body binding site, would be a particularly interesting
variable to measure in the context of anti-CSP IgG-
mediated immunity, since the time of interaction with
the parasite is short (less than 30 minutes [9]), sporozo-
ites are strongly diluted and few. In fact, only one suc-
cessful hepatocyte infection is sufficient to initiate and
maintain blood stage infection. Studies in mice have
shown that high antibody affinity against a synthetic
CSP immunogen is positively associated with protection
[8,10] and most studies in humans indicate that anti-
CSP IgG concentration explains only parts of the
vaccine-mediated protection. Increase in antibody affin-
ity after repeated antigen exposure is the result of affin-
ity maturation due to somatic hypermutation. The rate
and extent of maturation may be influenced by several
factors, including nature, route and dose of the antigen,
adjuvants and carriers as well as the immunization
schedule. In the present study antibody avidity was mea-
sured. It is a representation of the strength of interaction
between antibodies and antigens in a complex and be-
sides antibody affinity, valences of antibodies and anti-
gens as well as structural features of the complex are
important determinants of avidity. For CSP, it has been
shown that the use of some adjuvants can increase the
avidity of anti-CSP IgG after vaccination of human vol-
unteers [11]. In this study IgG avidity against the repeat
region of CSP was measured after the second and third
injection of RTS,S/AS01E in infants that received thevaccine as part of a phase IIb clinical trial to assess safety
and efficacy of RTS,S/AS01E in the age-group targeted by
the expanded programme on immunization (EPI) [5,12].
Methods
Clinical trial
The objective of the study was to explore the effect of
anti-CSP IgG avidity on RTS,S vaccine efficacy in naturally
exposed infants. Details of the clinical trial have been pub-
lished previously [5,12]. Briefly, safety and efficacy of RTS,
S/AS01E when given through the EPI was assessed in 511
children from Gabon, Ghana and Tanzania. Participants
were randomly assigned to one of three intervention arms:
1) RTS,S/AS01E as three injections, one month apart (0, 1,
2 months schedule [012]; n = 170), 2) RTS,S/AS01E ex-
tended schedule (0, 1, 7 months schedule [017]; n = 170)
or 3) control (EPI vaccines alone; n = 171). Malaria was
defined as parasitaemia >500 parasites per μl and an axil-
lary temperature >37°C. The efficacy of RTS,S against first
malaria episodes, detected by passive case detection, was
equivalent in the two schedules one year after the third
injection. The study followed Good Clinical Practice
guidelines, the Declaration of Helsinki (4th revision) and
received approval from the appropriate local and national
ethics committees of each site. In addition, ethical re-
view by the ethics committees of the London School of
Hygiene and Tropical Medicine Ethic Committee, the
Swiss Tropical Institute Committee and the Western
Institutional Review Board was sought. The trial is
registered with ClinicalTrials.gov (NCT00436007).
Antibody measurements
Antibodies against CSP were measured by evaluating
IgG responses against the CSP-repeat region, using a
validated enzyme-linked immunosorbent assay (ELISA)
with R32LR as the coating antigen [13]. An anti-CSP
IgG titre of 0.5 ELISA units per millilitre (EU/mL) or
greater was considered to be positive. For measurements
of avidity of IgG against the repeat region of CSP,
samples were evaluated as described [13], but in two dif-
ferent plates; one treated with a chaotropic agent and
one untreated plate. As chaotropic agent a 1 M solution
of ammonium thiocyanate (NH4SCN) was added in the
treatment plate while 0.05% Tween-20 in PBS was added
in the untreated plate and both CSP ELISA plates were
further washed and developed as described [13]. The
avidity index (AI) was calculated as the ratio of the con-
centration of anti-CSP IgG (EU/ml) that remained
bound to the coated antigen after treatment with
NH4SCN, divided by the concentration of IgG (EU/ml)
that remained bound to the coated antigen in the un-
treated plate. Anti-CSP IgG quantification and avidity
were measured at the Center for Vaccinology, Ghent
University Hospital, Belgium.
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concentration was used since previous data showed that
log-transformation results in a better fit to the normal
distribution. AI was analysed in the two RTS,S-vacci-
nated arms and after the second and third vaccination.
Since the majority of infants before vaccination and
those receiving control vaccine do not have measurable
anti-CSP IgG, AI cannot be calculated. Delta AI (dAI)
was defined as the difference in AI between the second
and third vaccination. Similarly, delta CSP (dCSP) was
defined as the difference in anti-CSP IgG concentration
between the second and third vaccination.
Statistics
Analysis of the effect of IgG avidity on protective effi-
cacy was exploratory and not detailed in the statistical
analysis plan of the original study. IgG responses be-
tween the groups were analysed by descriptive statistics
and represented as boxplots together with the individual
measurements. The effect of anti-CSP IgG concentration
and AI on risk of malaria was calculated using the
according-to-protocol (ATP) dataset with a Cox propor-
tional hazards model in R v2.15.2. For statistical model-
ling antibody concentrations were log-transformed. To
calculate the effect of dAI and dCSP on the occurrence
of malaria episodes with a Cox proportional hazards
model, values were dichotomized on the median dAI or
dCSP and labelled as ‘high’ and ‘low’, respectively. All
models included the covariates schedule and site. If ap-
propriate, other covariates were added as reported in the
results section. A p-value below 0.05 was considered sig-
nificant and 95% confidence intervals (95% CI) are given
where appropriate.
Results
After screening 605 participants, 170 received RTS,S in
the standard (012) and 170 in the extended (017)
schedule, as depicted on the CONSORT flowchart of
the primary study (Figure 1). Samples from 315 (300
ATP) participants were available for immunological
analysis (012: n = 154 [148]; 017: n = 161 [152]). Paired
immunological samples to calculate dAI were available
from 187 (179 ATP) participants (012: n = 103 [100];
017: n = 84 [79]).
As reported earlier [5], high anti-CSP IgG titres after
three vaccine injections were associated with a reduc-
tion in subsequent incidence of clinical malaria: the
hazard ratio of a ten-fold increase in anti-CSP IgG was
0.52 (95% CI: 0.34-0.81), which corresponds to a 48%
risk reduction.
Absolute AI after two (012: 35.9, 017: 34.9; t-test p = 0.57)
and three (012: 41.2, 017: 39.3; t-test p = 0.22) RTS,S injec-
tions were similar between the two vaccination schedules
(Figure 2). As expected, an increase in AI between thesecond and third vaccination was present (Figure 3). In-
crease in delta AI (dAI) was slightly, albeit not statistically
significant, higher in the 017 (7.1) group compared to the
012 (4.2) group (delta: 3.0; 95% CI: −0.3-6.1; t-test p = 0.08).
To explore the effect of AI, dAI and dCSP on malaria
risk, three Cox proportional hazard models were defined
and tested. AI after the third injection, corrected for site,
schedule and anti-CSP IgG concentration, did not ex-
plain a significant reduction in risk of clinical malaria
(Model 1; hazard ratio: 0.99, 95% CI: 0.97-1.02). Partici-
pants were then divided on the median in dCSP and dAI
‘high’ and ‘low’ responders and included as categorical
variable in the model. Classification as ‘high-dCSP’ was
associated with a significant risk reduction (77%) com-
pared to the ‘low dCSP’ group in a model corrected for
site and schedule (Model 2; hazard ratio: 0.23, 95% CI:
0.11-0.51). When dAI, corrected for site, schedule and
dCSP was analysed, the hazard ratio between high and
low responders separated by the median, was 0.46
(Model 3; 95% CI: 0.22-0.99; Wald test p = 0.049), hence
classification as ‘high dAI’ group member is associated
with a 54% risk reduction (Figure 4).
Discussion
The complex interplay of vaccine-primed immune medi-
ators that define a successful response upon pathogen
encounter is not well understood. Cellular and humoral
components have important roles, although in various
compositions, depending on the pathogen and the host.
Antibodies are the prototypic vaccine-induced immune
mediators and play an important role in anti-malarial
immunity during the pre-erythrocytic [8,10] as well as
the erythrocytic stage [14] of the disease, as shown by
passive transfer experiments in mice and man. The sheer
concentration of antigen-specific antibodies is normally
used to measure immunization success and serves as a
surrogate to estimate protective efficacy. The clinical de-
velopment of RTS,S is a unique opportunity to investi-
gate the effect of further variables such as antibody
avidity, isotype or subclass on vaccine efficacy, since
clinical (true) efficacy is known [5], being 57% (95% CI:
33–73) with the 012 schedule and 32% (95% CI: 16–45)
following the 017 schedule.
Here, anti-CSP IgG avidity was measured to assess if it
predicts vaccine efficacy in a phase II clinical trial of
RTS,S independent of anti-CSP IgG concentration
[5,12]. Regardless of the vaccination scheme and site,
avidity did not improve prediction over anti-CSP IgG
concentration alone. This may mean that: i) the assay is
not sensitive enough to reflect avidity; ii) collinearity be-
tween antibody concentration and avidity blurs the effect
of avidity; or, iii) that avidity is not an important deter-
minant of vaccine efficacy. In this study IgG concentra-
tion and avidity was measured after the second and third
Figure 1 CONSORT study flow chart.
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immune system reacted to vaccination successfully.
Since kinetics of IgG vary over time and the study was
performed under natural exposure to malaria parasites,
the time of encounter with the parasite becomes an im-
portant variable. This is in contrast to controlled humanmalaria infection (CHMI) studies, where the time of in-
fection is defined. Hypothetically, the difference in IgG
concentration (and avidity) between second and third
vaccination could be a better predictor of effective
antibody-mediated protection than concentration after
the third vaccine injection, because it better reflects the
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Figure 4 Kaplan Meier plot of malaria episodes over time in
participants classified as having high (black) or low (grey) dAI.
Figure 2 Box-plot and single measurements of absolute AI at
second and third vaccination using two vaccination schedules
(012 or 017).
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site encounter. The present data argue for the use of this
approach since it was shown that a high dCSP predicts
protective efficacy and dAI explains part of the protec-
tion in the RTS,S vaccinated children (Model 3). How
AI evolves over time and if it is a useful predictor ofFigure 3 Box-plot and single measurements of difference in AI
(dAI) between second and third vaccination using two
vaccination schedules (012 or 017). Note that for the analysis of
dAI only paired samples were used (n = 179).vaccine efficacy remains to be validated with further, in-
dependent and confirmatory studies.
Nevertheless, this observation adds a new component
to the search of correlates of protection and the under-
standing of the immune responses elicited by pre-
erythrocytic malaria vaccine candidates such as RTS,S.
Since adjuvants also have a profound effect on the speed
of avidity maturation [11], the effect of avidity on vac-
cine efficacy could even be analysed with interventional
studies that assess the effect of timing between immuni-
zations (as in this study) and different adjuvants on pro-
tective efficacy while direct measures of maturation of
the immune system such as single-cell based sequencing
of IgG genes of anti-CSP memory B-cells [15,16] are
performed. This may be particularly interesting for anti-
gens such as CSP that are not highly immunogenic per
se, because highly immunogenic antigens often induce
antibodies with strong avidity over a short period of time
and a threshold antibody concentration is appropriate to
predict their efficacy [17]. Other studies in the develop-
ment of RTS,S (e.g., challenge experiments [18] and the
recently completed phase III trial [1-3]) will certainly
provide additional information and may establish the
measurement of avidity as one biomarker for vaccine effi-
cacy. Additionally, such knowledge may guide the design
of next generation vaccines and administration schemes.
Conclusions
So far, the most robust correlate of protection for the mal-
aria vaccine candidate RTS,S is anti-circumsporozoite
(CSP) IgG concentration following immunization. Pre-
clinical data and theoretical considerations suggest that
avidity may have an additional impact on protective
Ajua et al. Malaria Journal  (2015) 14:72 Page 6 of 6efficacy. It is shown that an increase in anti-CSP IgG con-
centration and avidity between second and third vaccine
injection is associated with a strong risk-reduction for
malaria after immunization. This finding shall influence
the way of analysis of immunological correlates of protec-
tion since using change in antibody concentration and
avidity rather than single measurements enables improved
modelling of immune-effector function at the time of
pathogen encounter and hence more powerful prediction
of vaccine efficacy.
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Abbreviations
AI: Avidity index; dAI: delta AI; CSP: Plasmodium falciparum circumsporozoite
protein; dCSP: Delta CSP; ATP: according to protocol; IgG: Immunoglobulin G.
Competing interests
This study was funded by PATH-MVI and GlaxoSmithKline Biologicals SA. GM
and MT report receiving funding for study-related travels. MT reports receiving
financial compensation for activities outside the submitted work for board
membership of the Optimus Foundation and the Novartis Institute for Tropical
Diseases, having grants pending from both PATH-MVI and the Bill and Melinda
Gates Foundation, and receiving travel reimbursements from PATH-MVI and
Sanaria Corp. JV, EJ, ML, and PC are employees of the GlaxoSmithKline group of
companies. JV, EJ and ML receive GlaxoSmithKline stock and/or options. CFO is
an employee of PATH-MVI. Other authors report no conflicts of interest other
than study funding.
Authors’ contributions
AA and BM drafted the manuscript and performed the statistical analysis. BL,
STA, KPA, SO-A, GM, MM, and NS collected the data and performed analyses.
MT, SA, JV, EJ, ML, PC, CFO, and PGK conceived and supervised the study. All
authors contributed to writing and review of the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
The authors thank the participants and their parents, the community
members and the Chiefs in the traditional areas, and the management and
staff of the local collaborating institutions (the Kintampo Municipal Hospital,
Ghana Health Service, and the Kintampo North and South Health Directorates
in Kintampo). We also thank Jarno Jansen (Keyrus Biopharma, on behalf of GSK
Vaccines) for publication management and editorial assistance. The Deutsche
Forschungsgemeinschaft and the Open Access Publishing Fund of the
University of Tübingen supported publishing this manuscript under a Creative
Commons Attribution License.
Author details
1Eberhard Karls Universität Tübingen, Institut für Tropenmedizin, Wilhelmstraße
27, 72074 Tübingen, Germany. 2Centre de Recherches Médicales de Lambaréné
(CERMEL), BP118 Lambaréné, Gabon. 3Kintampo Health Research Centre, PO
Box 200, Kintampo, Ghana. 4Faculty of Infectious and Tropical Diseases, London
School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
5Bagamoyo Research and Training Centre of Ifakara Health Institute, Bagamoyo,
360 Kiko Avenue, Mikocheni, PO Box 78373, Dar es Salaam, Tanzania.
6Swiss Tropical and Public Health Institute, Basel, Switzerland. 7GlaxoSmithKline
Biologicals, Rixensart, Belgium. 8PATH Malaria Vaccine Initiative, 455
Massachusetts Avenue NW, Suite 1000, Washington, DC 20001, USA.
Received: 9 October 2014 Accepted: 2 February 2015References
1. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BGNO, Kabwende
AL, et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N
Engl J Med. 2012;367:2284–95.
2. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP,
Conzelmann C, et al. First results of phase 3 trial of RTS, S/AS01 malaria
vaccine in African children. N Engl J Med. 2011;365:1863–75.
3. RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria
vaccine during 18 months after vaccination: a phase 3 randomized,
controlled trial in children and young infants at 11 African sites. PLoS Med.
2014;11:e1001685.
4. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, et al.
Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on
anti-circumsporozoite antibody titres and protection in children aged
5–17 months in Kenya and Tanzania: a randomised controlled trial. Lancet
Infect Dis. 2011;11:102–9.
5. Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, et al.
Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with
expanded-programme-on-immunisation vaccines: 19 month follow-up of a
randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011;11:741–9.
6. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, et al.
Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a
highly endemic area of Mozambique: a double blind randomised controlled
phase I/IIb trial. Lancet. 2007;370:1543–51.
7. Egan JE, Weber JL, Ballou WR, Hollingdale MR, Majarian WR, Gordon DM,
et al. Efficacy of murine malaria sporozoite vaccines: implications for human
vaccine development. Science. 1987;236:453–6.
8. Porter MD, Nicki J, Pool CD, Debot M, Illam RM, Brando C, et al. Transgenic
parasites stably expressing full-length Plasmodium falciparum circumsporozoite
protein as a model for vaccine down-selection in mice using sterile protection
as an endpoint. Clin Vaccine Immunol. 2013;20:803–10.
9. Fairley H. Chemotherapeutic suppression and prophylaxis in malaria. Trans R
Soc Trop Med Hyg. 1945;38:311–55.
10. Reed RC, Louis-Wileman V, Wells RL, Verheul AF, Hunter RL, Lal AA.
Re-investigation of the circumsporozoite protein-based induction of sterile
immunity against Plasmodium berghei infection. Vaccine. 1996;14:828–36.
11. Rickman LS, Gordon DM, Wistar Jr R, Krzych U, Gross M, Hollingdale MR, et al.
Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl
lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet.
1991;337:998–1001.
12. Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R,
et al. Evaluation of the safety and immunogenicity of the RTS, S/AS01E
malaria candidate vaccine when integrated in the expanded program of
immunization. J Infect Dis. 2010;202:1076–87.
13. Clement F, Dewar V, Van Braeckel E, Desombere I, Dewerchin M, Swysen C, et al.
Validation of an enzyme-linked immunosorbent assay for the quantification of
human IgG directed against the repeat region of the circumsporozoite protein
of the parasite Plasmodium falciparum. Malar J. 2012;11:384.
14. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H,
Chantavanich P, et al. Parasitologic and clinical human response to
immunoglobulin administration in falciparum malaria. Am J Trop Med
Hyg. 1991;45:297–308.
15. Busse CE, Czogiel I, Braun P, Arndt PF, Wardemann H. Single-cell based
high-throughput sequencing of full-length immunoglobulin heavy and light
chain genes. Eur J Immunol. 2014;44:597–603.
16. Muellenbeck MF, Ueberheide B, Amulic B, Epp A, Fenyo D, Busse CE, et al.
Atypical and classical memory B cells produce Plasmodium falciparum
neutralizing antibodies. J Exp Med. 2013;210:389–99.
17. Bachmann MF, Kalinke U, Althage A, Freer G, Burkhart C, Roost H, et al. The
role of antibody concentration and avidity in antiviral protection. Science.
1997;276:2024–7.
18. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A
preliminary evaluation of a recombinant circumsporozoite protein vaccine
against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation
Group. N Engl J Med. 1997;336:86–91.
